Researchers sought to determine if nonmyeloablative HSCT conditioning was noninferior to myeloablative approaches in more vulnerable patients with AML.
Patients receiving treosulfan and fludarabine experienced improved event-free and overall survival compared with patients receiving busulfan and fludarabine.
This study investigated whether T-cell gene-expression profiles and other molecular characteristics of T-cell populations were associated with CAR-T performance.
The FDA has approved Ziextenzo (pegfilgrastim-bmez; Sandoz), a biosimilar to Neulasta.
A hematologic score based on specific blood parameters was evaluated for its potential to predict survival in patients with newly diagnosed multiple myeloma.
The response rate to 19-28z CAR-T therapy was 100% for those with pretreatment MRD who received preconditioning chemotherapy with high-dose cyclophosphamide.
Using a matched study, researchers sought to determine the effect of skeletal-related events (SREs) on health care costs for patients with NDMM.
Overall survival significantly longer, percentage of remission higher than with salvage chemotherapy.
Optimal thromboprophylaxis for VTE was found to be essential in patients with NDMM, especially those at high risk.
A new study aims to address the conundrum of coagulation risk in patients hospitalized for hematologic malignancies.
